Anticancer bioactive peptide inhibits gastric cancer progression by regulating the long non-coding RNA MIR22HG

Anticancer bioactive peptide (ACBP), a novel antitumor agent isolated from goat liver immunized with a human gastric cancer (GC) extract in our lab, shows significant and effective inhibition of tumor cell proliferation in GC. Long noncoding RNAs (LncRNAs) have been shown to play a key role in the progression of GC. However, the regulatory effect of ACBP on LncRNA for Gastric cancer (GC) remains unclear. This study investigated the potential preventive and therapeutic role of the ACBP-regulated MIR22HG. The biological roles of ACBP in GC cells were assessed using CCK-8 and EDU assays. The effect of ACBP on tumor growth was determined by a subcutaneous xenograft model.Methylation analysis, RNA pull-down assay, RNA immunoprecipitation (RIP) assay, and chromatin immunoprecipitation assays were performed to evaluate the function and mode of action of the LncRNA MIR22HG/ protein arginine methyltransferase 5 (PRMT5) /FOXP1 axis. In this study, we found that ACBP can inhibit GC cell proliferation and invasion in vitro and in vivo. ACBP upregulates LncRNA MIR22HG expression by suppressing the enrichment of EZH2 and H3K27me3 on the LncRNA MIR22HG promoter. The LncRNA MIR22HG activates FOXP1 transcription by recruiting the PRMT5 transcription factor to the FOXP1 promoter region. These results indicate that ACBP upregulates LncRNA MIR22HG and regulates FOXP1 to inhibit gastric cancer proliferation and migration, suggesting that it may play an essential role in predicting clinical outcome.